An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 301–400 of 1,001
Current and Future Challenges in Modern Drug Discovery
Tautermann, C. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_1 · Cited by 50
Adegbola, P. I., Semire, B., Fadahunsi, O. S., & Adegbola, A. E. (2021) · VirusDisease · doi:10.1007/s13337-021-00682-7 · Cited by 50
Qian, K., Stella, L., Jones, D. S., Andrews, G. P., Du, H., & Tian, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060889 · Cited by 50
Yıldırım, Z., Swanson, K., Wu, X., Zou, J., & Wu, J. C. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022724-095035 · Cited by 49
Winter, S., Fisel, P., Büttner, F., Rausch, S., D’Amico, D., Hennenlotter, J., Kruck, S., Nies, A. T., Stenzl, A., Junker, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29930 · Cited by 49
Fabini, E., & Danielson, U. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.054 · Cited by 49
Bioprinted three dimensional human tissues for toxicology and disease modeling
Nguyen, D. G., & Pentoney, S. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.03.001 · Cited by 49
In Silico Tools and Software to Predict ADMET of New Drug Candidates
Kar, S., Roy, K., & Leszczyński, J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_4 · Cited by 49
Latent Molecular Optimization for Targeted Therapeutic DesignPreprint
Aumentado‐Armstrong, T. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1809.02032 · Cited by 49
Lloyd, K. C. K., Adams, D. J., Baynam, G., Beaudet, A. L., Bosch, F., Boycott, K. M., Braun, R. E., Caulfield, M., Cohn, R., Dickinson, M. E., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-1931-9 · Cited by 42
Improved GNNs for Log D 7.4 Prediction by Transferring Knowledge from Low-Fidelity Data
Duan, Y., Fu, L., Zhang, X., Long, T.-Z., Yuan-Hang, H., Liu, Z., Lü, A., Deng, Y., Hsieh, C., Hou, T., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01564 · Cited by 48
Open Access Could Transform Drug Discovery: A Case Study of JQ1
Arshad, Z., Smith, J. A., Roberts, M., Lee, W. H., Davies, B. M., Bure, K., Holländer, G. A., Dopson, S., Bountra, C., & Brindley, D. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1144587 · Cited by 48
Potential of small-molecule fungal metabolites in antiviral chemotherapy
Roy, B. (2017) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206617705500 · Cited by 48
Podtelezhnikov, A. A., Monroe, J. J., Aslamkhan, A. G., Pearson, K., Qin, C., Tamburino, A. M., Loboda, A. P., Glaab, W. E., Sistare, F. D., & Tanis, K. Q. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa026 · Cited by 48
Reviving an R&D pipeline: a step change in the Phase II success rate
Wu, S. S., Fernando, K., Allerton, C. M. N., Jansen, K. U., Vincent, M. S., & Dolsten, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.019 · Cited by 48
Driving success in personalized medicine through AI-enabled computational modeling
Chakravarty, K., Antontsev, V. G., Bundey, Y., & Varshney, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.007 · Cited by 48
Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing
Madugula, S. S., John, L., Nagamani, S., Gaur, A. S., Poroikov, V., & Sastry, G. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104856 · Cited by 48
Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors
Pantsar, T., Kaiser, P. D., Kudolo, M., Förster, M., Rothbauer, U., & Laufer, S. (2022) · Nature Communications · doi:10.1038/s41467-022-28164-4 · Cited by 48
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
He, Y., Zheng, Y., Zhu, C., Peng, L., Yu, J., Tang, C., Chen, H., & Diao, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01104 · Cited by 47
Juguilon, C., Khosravi, R., Radisic, M., & Wu, J. C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325497 · Cited by 47
Current trends in in silico, in vitro toxicology, and safety biomarkers in early drug development
Loïodice, S., da Costa, A. N., & Atienzar, F. (2017) · Drug and Chemical Toxicology · doi:10.1080/01480545.2017.1400044 · Cited by 47
Kelm, J. M., Lal‐Nag, M., Sittampalam, G. S., & Ferrer, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.007 · Cited by 47
Prior, H. M., Baldrick, P., Beken, S., Booler, H. S., Bower, N., Brooker, P. C., Brown, P. C., Burlinson, B., Burns‐Naas, L. A., Casey, W., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104624 · Cited by 47
Compound high-quality criteria: a new vision to guide the development of drugs, current situation
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.005 · Cited by 46
Oja, M., & Maran, U. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.014 · Cited by 46
Liu, C., Wang, K., Zhuang, J., Gao, C., Li, H., Liu, L., Feng, F., Zhou, C., Yao, K., Deng, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01171 · Cited by 46
Precision Medicine and cardiac channelopathies: when dreams meet reality
Gnecchi, M., Sala, L., & Schwartz, P. J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab007 · Cited by 46
ADMET property prediction via multi-task graph learning under adaptive auxiliary task selection
Du, B.-X., Xu, Y., Yiu, S., Yu, H., & Shi, J. (2023) · iScience · doi:10.1016/j.isci.2023.108285 · Cited by 45
Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments
Kemas, A. M., Shafagh, R. Z., Taebnia, N., Michel, M., Preiss, L. C., Hofmann, U., & Lauschke, V. M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303561 · Cited by 45
Jia, X., Teutonico, D., Dhakal, S., Psarellis, Y. M., Abós, A., Zhu, H., Mavroudis, P. D., & Pillai, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00340 · Cited by 45
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies
Salvati, A., Melone, V., Giordano, A., Lamberti, J., Palumbo, D., Palo, L., Rea, D., Memoli, D., Simonis, V., Alexandrova, E., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06856-x · Cited by 45
Bateman-House, A., & Robertson, C. T. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.8167 · Cited by 45
Fischer, A., Sellner, M. S., Neranjan, S., Lill, M. A., & Smieško, M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11923239 · Cited by 45
Privileged natural product compound classes for anti-inflammatory drug development
Choo, M. Z. Y., Chua, J. A. T., Lee, S. X. Y., Ang, Y., Wong, W. S. F., & Chai, C. L. L. (2025) · Natural Product Reports · doi:10.1039/d4np00066h · Cited by 44
Mao, F., Kong, Q., Wei Min, N. I., Xu, X., Ling, D., Lu, Z., & Li, J. (2016) · ChemistryOpen · doi:10.1002/open.201600015 · Cited by 44
Curreli, F., Belov, D. S., Kwon, Y. D., Ramesh, R. R., Furimsky, A. M., O’Loughlin, K. G., Byrge, P. C., Iyer, L., Mirsalis, J. C., Kurkin, A. V., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.062 · Cited by 44
Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury
Kralj, T., Brouwer, K. L. R., & Creek, D. J. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab069 · Cited by 44
cropCSM: designing safe and potent herbicides with graph-based signatures
Pires, D. E. V., Stubbs, K. A., Mylne, J. S., & Ascher, D. B. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac042 · Cited by 44
Compilation and physicochemical classification analysis of a diverse hERG inhibition database
Didžiapetris, R., & Lanevskij, K. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9986-0 · Cited by 44
Masjosthusmann, S., Becker, D., Petzuch, B., Klose, J., Siebert, C., Deenen, R., Barenys, M., Baumann, J., Dach, K., Tigges, J., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.009 · Cited by 39
The future of drug development: the paradigm shift towards systems therapeutics
Danhof, M., Klein, K., Stolk, P., Aitken, M. L., & Leufkens, H. G. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.002 · Cited by 44
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
“Drugs that showed impressive potencies against 2D monolayers often failed in subsequent cost-intensive clinical trials [13, 14].”
BackgroundReimagining human-centric drug development with new approach methodologies
Wu, X., Wu, M. A., Zou, J., Kleinstreuer, N., & Wu, J. C. (2026) · Science · doi:10.1126/science.aeb0045 · Cited by 43
Zhu, Y., Zuo, W., Chen, L., Bian, S., Jing, J., Gan, C., Wu, X., Liu, H., Su, X., Hu, W., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.08.012 · Cited by 43
Timpe, C., Stegemann, S., Barrett, A., & Mujumdar, S. K. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14388 · Cited by 43
Ghose, A. K., Ott, G. R., & Hudkins, R. L. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00273 · Cited by 43
Russo, G., Grumetto, L., Szücs, R., Barbato, F., & Lynen, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01811 · Cited by 43
Seizure liability assessments using the hippocampal tissue slice: Comparison of non-clinical species
Accardi, M. V., Huang, H., & Authier, S. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.11.003 · Cited by 43
Automated De Novo Drug Design: Are We Nearly There Yet?
Schneider, G., & Clark, D. E. (2019) · Angewandte Chemie · doi:10.1002/ange.201814681 · Cited by 43
Curreli, F., Ahmed, S., Victor, S. M. B., Iusupov, I. R., Belov, D. S., Markov, P. O., Kurkin, A. V., Altieri, A., & Debnath, A. K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02149 · Cited by 42
Mullane, K., & Williams, M. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.002 · Cited by 42
Meanwell, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00915 · Cited by 42
Access to Cyclopropyl-Fused Azacycles via a Palladium-Catalyzed Direct Alkenylation Strategy
Ladd, C. L., & Charette, A. B. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b02982 · Cited by 42
Detecting similar binding pockets to enable systems polypharmacology
Duran‐Frigola, M., Siragusa, L., Ruppin, E., Barril, X., Cruciani, G., & Aloy, P. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005522 · Cited by 42
A novel lab-on-a-chip platform for spheroid metabolism monitoring
Alexander, F., Eggert, S., & Wiest, J. (2017) · Cytotechnology · doi:10.1007/s10616-017-0152-x · Cited by 42
Designing small molecules for therapeutic success: A contemporary perspective
Maurer, T. S., Edwards, M. P., Hepworth, D., Verhoest, P. R., & Allerton, C. M. N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.017 · Cited by 42
How does basic research improve innovation performance in the world’s major pharmaceutical firms?
Leten, B., Kelchtermans, S., & Belderbos, R. (2021) · Industry and Innovation · doi:10.1080/13662716.2021.1997723 · Cited by 42
Andersson, T. B. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12804 · Cited by 39
Hansen, A. H., Sergeev, E., Bolognini, D., Sprenger, R. R., Ekberg, J. H., Ejsing, C. S., McKenzie, C. J., Ulven, E. R., Milligan, G., & Ulven, T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00855 · Cited by 41
Zmuda, F., Sastry, L., Shepherd, S. M., Jones, D. C., Scott, A., Craggs, P. D., Cortés-Cabrera, Á., Gray, D. W., Torrie, L. S., & Rycker, M. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00309-19 · Cited by 41
Palabindela, R., Guda, R., Gondru, R., Bodapati, R., Nukala, S. K., Myadaraveni, P., Ravi, G., & Kasula, M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134633 · Cited by 41
How Reliable Are Ligand-Centric Methods for Target Fishing?
Peón, A., Dang, C. C., & Ballester, P. J. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00015 · Cited by 41
Prediction of Small-Molecule Developability Using Large-Scale In Silico ADMET Models
Beckers, M., Sturm, N., Sirockin, F., Fechner, N., & Stiefl, N. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01083 · Cited by 40
Chirra, S., Gondru, R., Munikumar, M., Azam, M., Al-Resayes, S. I., Manchal, R., & Narsimha, S. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137803 · Cited by 40
Sistare, F. D., Mattes, W. B., & LeCluyse, E. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw025 · Cited by 40
A simple model to solve a complex drug toxicity problem
Dixit, V. A. (2018) · Toxicology Research · doi:10.1039/c8tx00261d · Cited by 40
Rushed Innovation: Evidence from Drug Licensing
Hermosilla, M. (2020) · Management Science · doi:10.1287/mnsc.2019.3530 · Cited by 40
Phillips, J. A., Grandhi, T. S. P., Davis, M., Gautier, J.-C., Hariparsad, N., Keller, D., Sura, R., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00925f · Cited by 38
Rood, J. J. M., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.06.037 · Cited by 40
Bachovchin, K. A., Sharma, A., Bag, S., Klug, D. M., Schneider, K. M., Singh, B., Jalani, H. B., Buskes, M. J., Mehta, N., Tanghe, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01365 · Cited by 40
Günaydin, H., & Bartberger, M. D. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00099 · Cited by 40
Zou, Y., Zhang, G., Li, C., Long, H., Chen, D., Li, Z., Ouyang, G., Zhang, W., Zhang, Y., & Wang, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021450 · Cited by 39
Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs
Teixeira, L. D. S., Chagas, T. V., Alonso, A., González‐Álvarez, I., Bermejo, M., Polli, J. E., & Rezende, K. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100988 · Cited by 39
Mizoi, K., Arakawa, H., Yano, K., Koyama, S., Kojima, H., & Ogihara, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100374 · Cited by 36
Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions
Pun, S., Haney, L. C., & Barrile, R. (2021) · Micromachines · doi:10.3390/mi12101250 · Cited by 39
A deep learning platform to assess drug proarrhythmia risk
Serrano, R., Feyen, D. A. M., Bruyneel, A. A. N., Hnatiuk, A. P., Vu, M. M., Amatya, P. L., Perea‐Gil, I., Prado, M., Seeger, T., Wu, J. C., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.12.002 · Cited by 38
Artificial intelligence in parasitic disease control: A paradigm shift in health care
Parija, S. C., & Poddar, A. (2024) · Tropical parasitology · doi:10.4103/tp.tp_66_23 · Cited by 38
Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics
Zou, M., Zhou, H., Gu, L., Zhang, J., & Fang, L. (2024) · Biology · doi:10.3390/biology13080555 · Cited by 38
State of the evidence: a survey of global disparities in clinical trials
Marshall, I. J., L’Esperance, V., Marshall, I. J., Thomas, J., Noel-Storr, A. H., Soboczenski, F., Nye, B., Nenkova, A., & Wallace, B. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004145 · Cited by 38
Engineering Cardiac Tissue for Advanced Heart‐On‐A‐Chip Platforms
Chen, X., Liu, S., Han, M., Long, M., Li, T., Hu, L., Wang, L., Huang, W., & Wu, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301338 · Cited by 38
Schittny, A., Ogawa, H., Huwyler, J., & Puchkov, M. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.09.011 · Cited by 38
Sustainable Practices in Medicinal Chemistry Part 2: Green by Design
Aliagas, I., Berger, R., Goldberg, K., Nishimura, R. T., Reilly, J., Richardson, P., Richter, D., Sherer, E. C., Sparling, B. A., & Bryan, M. C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01837 · Cited by 37
Śniecikowska, J., Głuch‐Lutwin, M., Bucki, A., Więckowska, A., Siwek, A., Jastrzębska‐Więsek, M., Partyka, A., Wilczyńska, D., Pytka, K., Pociecha, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00062 · Cited by 37
Low, L. A., Sutherland, M. L., Lumelsky, N. L., Selimović, Š., Lundberg, M. S., & Tagle, D. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36588-2_3 · Cited by 37
Mamoshina, P., Bueno‐Orovio, A., & Rodríguez, B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00639 · Cited by 37
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets
Rubbini, D., Cornet, C., Terriente, J., & Donato, V. D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220926920 · Cited by 37
Lall, M. S., Bassyouni, A., Bradow, J., Brown, M. S., Bundesmann, M. W., Chen, J., Ciszewski, G. M., Hagen, A. E., Hyek, D., Jenkinson, S. G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00483 · Cited by 37
Kropiwnicki, E., Evangelista, J. E., Stein, D. J., Clarke, D. J. B., Lachmann, A., Kuleshov, M. V., Jeon, M., Jagodnik, K. M., & Ma’ayan, A. (2021) · Database · doi:10.1093/database/baab017 · Cited by 37
Dambach, D. M., Misner, D., Brock, M., Fullerton, A. M., Proctor, W. R., Maher, J. M., Lee, D. H., Ford, K. A., & Diaz, D. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00396 · Cited by 37
Shah, F., Stepan, A. F., O’Mahony, A., Velichko, S., Folias, A. E., Houle, C. D., Shaffer, C. L., Marcek, J. M., Whritenour, J., Stanton, R. V., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.003 · Cited by 37
Srinivasan, S., Yee, N. A., Zakharian, M., Alečković, M., Mahmoodi, A., Nguyen, T., & Oneto, J. M. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.28.534654 · Cited by 37
Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy
Rahman, L., Khalil, A. T., Shahid, S. A., Shinwari, Z. K., Almarhoon, Z. M., Alalmaie, A., Sharifi‐Rad, J., & Călina, D. C. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4271 · Cited by 36
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction
Fan, N., Chen, J., Wang, J., Chen, Z., & Yang, Y. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104487 · Cited by 36
Self-citationDrawnel, F., Zhang, J. D., Küng, E., Aoyama, N., Benmansour, F., Rosario, A. A. D., Zoffmann, S., Delobel, F., Prummer, M., Weibel, F., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.03.016 · Cited by 36
Kumar, S. U., Priya, N. M., Nithya, S., Kannan, P., Jain, N., Kumar, D. T., Magesh, R., Younes, S. N., Zayed, H., & Doss, C. G. P. (2021) · 3 Biotech · doi:10.1007/s13205-021-02749-0 · Cited by 36
Few-shot learning with transformers via graph embeddings for molecular property prediction
Torres, L. H. M., Ribeiro, B., & Arrais, J. P. (2023) · Expert Systems with Applications · doi:10.1016/j.eswa.2023.120005 · Cited by 36
Naidoo, D., Roy, A., Slavětínská, L. P., Chukwujekwu, J. C., Gupta, S., & Staden, J. V. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112305 · Cited by 36
The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research
Huber, R. J., Hughes, S. M., Liu, W., Morgan, A., Tuxworth, R. I., & Russell, C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165614 · Cited by 36
Lin, X., & Farooqi, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.012 · Cited by 36
Opportunities to Apply the 3Rs in Safety Assessment Programs
Sewell, F. R., Edwards, J., Prior, H. M., & Robinson, S. (2016) · ILAR Journal · doi:10.1093/ilar/ilw024 · Cited by 35
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.